MedTrace Logo

Pilot Study About Safety and Efficacy of Atomized Intrapleural Lidocaine During Pleuroscopy

NCT00693043 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2017-12-26

No results posted yet for this study

Summary

This study will evaluate the potential to decrease the use of IV anesthesia drugs in patients undergoing pleuroscopy administering lidocane standardly applied to the skin in combination with atomized lidocaine applied into the pleural cavity.

Conditions

Interventions

DRUG

lidocaine hydrochloride

Study group will have up to 2 mg/kg of Lidocaine administered to the skin and additional Lidocaine(3mg/kg)infused through an atomizer using a specialized tip attached to the sterile leur lock syringe into the pleural cavity. The Intrapleural lidocaine dose will be given in a fixed dose of 3 mg/kg. Serum levels will be obtained at 30, 60, and 120 minutes after initial intradermal administration

Sponsors & Collaborators

  • Lahey Clinic

    lead OTHER

Principal Investigators

  • David R Riker, MD · Lahey Clinic

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2010-03-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00693043 on ClinicalTrials.gov